SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2026
Comorbidities in clinical cohorts of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComorbidities can influence treatment decisions and health outcomes in patients with idiopathic pulmonary fibrosis (IPF). This systematic review and meta-analysis evaluated the types and prevalence of comorbidities, as well as their impact on health outcomes, in clinical cohorts of patients with IPF.
methodsOvid MEDLINE and Embase were searched up to August 2024 for eligible observational studies with ≥100 adults with IPF that reported at least one comorbidity. Meta-analyses were performed for comorbidity prevalence, with associations between comorbidities and health outcomes narratively synthesised.
resultsA total of 251 studies (n=606 398 participants) were included. Common comorbidities were systemic hypertension (pooled prevalence 39%, 95% confidence interval (CI) 34-44%), dyslipidaemia (30%, 95% CI 20-38%), gastro-oesophageal reflux disease (27%, 95% CI 23-31%), hiatus hernia (20%, 95% CI 9-33%), overweight/obesity (22%, 95% CI 18-27%), diabetes mellitus (21%, 95% CI 19-23%), ischaemic heart disease (20%, 95% CI 17-23%) and heart failure (15%, 95% CI 13-18%). Few studies evaluated the relationships between comorbidities and health-related quality of life or IPF disease progression. Lung cancer was the only comorbidity that was consistently associated with increased short-term and long-term mortality in patients with IPF.
conclusionsA wide variety of comorbidities affect clinically encountered patients with IPF, with many having higher prevalence rates than those reported in clinical trial cohorts. This highlights the need for personalised care in the management of IPF. The relationships between different comorbidities and health outcomes warrant future studies to better inform targeted screening and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.